Möchten Sie immer auf dem neuesten Stand bleiben?

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into an agreement to acquire Definiens, a privately -held company that has pioneered a...

AstraZeneca today announced that it has completed the strategic transaction to transfer the rights to Almirall's respiratory franchise to the company. As previously...

US FDA APPROVES ONCE-DAILY XIGDUO™ XR TABLETS FOR ADULTS WITH TYPE 2 DIABETES First US approval for once-daily tablet combining SGLT2 inhibitor and metformin HCl extended-release AstraZeneca today...

LYNPARZA™ (olaparib) RECEIVES POSITIVE CHMP OPINION in the EU for the MAINTENANCE treatment of BRCA-mutated Platinum sensitive relapsed ovarian CANCER AstraZeneca today announced that the Committee...

Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 1 October 2014, the interest of Mr Pascal Soriot, a person discharging managerial responsibilities, in the...

AstraZeneca has presented new data from its pipeline of investigational cancer medicines at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid. Together with MedImmune, its global...

Moventig® (naloxegol) receives positive CHMP opinion in the EU for the treatment of adults with opioid-induced constipation AstraZeneca today announced that the Committee for Medicinal Products for...

FDA APPROVES MOVANTIK™ (naloxegol) TABLETS C-II FOR THE TREATMENT OF OPIOID -INDUCED CONSTIPATION IN ADULT PATIENTS WITH CHRONIC NON-CANCER PAIN AstraZeneca today announced that the US Food and Drug...

ASTRAZENECA AND LILLY ANNOUNCE ALLIANCE TO DEVELOP AND COMMERCIALISE BACE INHIBITOR AZD3293 FOR ALZHEIMER'S DISEASE AstraZeneca and Eli Lilly and Company (Lilly) today announced an agreement...

Transactions by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 1 September 2014, Luke Miels, EVP, Global Product and Portfolio Strategy, a person discharging managerial...